ConferenceProstate Cancer Prostatic Dis · September 2022
BACKGROUND: Prostate cancer is a clinically and molecularly heterogeneous disease, with highest incidence and mortality among men of African ancestry. To date, prostate cancer patient-derived xenograft (PCPDX) models to study this disease have been difficu ...
Full textOpen AccessLink to itemCite
ConferenceJournal of Clinical Oncology · February 20, 2022
167 Background: Low PSMA uptake on positron-emission tomography is seen in up to 30% of mCRPC pts and represents a clinically distinct subgroup with adverse outcomes. We assessed transcriptional and clinical features associated w ...
Full textCite
ConferenceJournal of Clinical Oncology · February 20, 2021
89 Background: Men with metastatic neuroendocrine/small cell and aggressive variant prostate cancer (NEPC/AVPC) have poor outcomes despite platinum and taxane chemotherapy. These tumors share common features with small cell lung ...
Full textCite
ConferenceCancer Epidemiology, Biomarkers & Prevention · June 1, 2020
AbstractBackground: Prostate cancer (PCa) is a clinically and molecularly heterogeneous disease, with differences in incidence and mortality among and between racial groups, which grade and stage only partia ...
Full textCite
ConferenceIEEE International Ultrasonics Symposium Ius · October 1, 2019
Prostate cancer diagnosis using standard transrectal ultrasound (TRUS) and systematic biopsy is challenging. To improve the performance of TRUS imaging, we combined it with acoustic radiation force impulse (ARFI) imaging and shear wave elasticity imaging ( ...
Full textCite
ConferenceCancer Research · July 1, 2019
AbstractBackground A paradigm shift from single marker immunohistochemistry (IHC) to multiplexing in molecular histopathology has helped better understand the cellular composition and heterogeneity of sub ...
Full textCite
ConferenceJournal of Clinical Oncology · May 20, 2019
e14259 Background: Immune checkpoint inhibitors (ICIs) are standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. PD-L1 positivit ...
Full textCite
ConferenceJournal of Clinical Oncology · March 1, 2019
577 Background: Immune checkpoint inhibitors (ICIs) are now standard of care for mRCC and mUC patients (pts). PD-L1 status is gaining importance as a predictive biomarker, particularly for cisplatin-ineligible mUC. Four different ...
Full textCite
ConferenceCancer Research · August 15, 2018
AbstractMetastatic progression in patients with prostate cancer is common despite pharmacologic inhibition of androgen receptor signaling. This drug resistance is associated with increased signaling through ...
Full textCite
ConferenceCancer Research · July 1, 2018
AbstractPurpose: Assessment of PD-L1 expression is a critical part of patient management for immunotherapy. However, studies have shown that pathologist-based analysis lacks reproducibility, especially for i ...
Full textCite
ConferenceJournal of Clinical Oncology · February 20, 2018
278 Background: Detection of t-SCNC in mCRPC patients relies primarily on histopathologic evaluation (Histo) of a metastatic tumor biopsy (bx), likely leading to underdiagnosis. The clinical features of t-SCNC and the diagnostic ...
Full textCite
ConferenceJournal of Clinical Oncology · February 20, 2018
197 Background: The PAM50 gene expression classifier (PAM50) identifies luminal and basal subtypes and predicts response to androgen deprivation therapy in localized prostate cancer. The clinical utility of using PAM50 to molecul ...
Full textCite
ConferenceJournal of Clinical Oncology · February 10, 2012
109 Background: The objective was to measure the added benefit of multi-parametric endorectal coil prostate MRI (eMRI) to traditional active (AS) criteria in delineating men with more advanced disease. Methods: ...
Full textCite
https://orcid.org/0000-0003-1195-1998